Total Payments
$1.0M
2024 Payments
$146,542
Companies
24
Transactions
819
Medicare Patients
9,357
Medicare Billing
$13.7M
Payment Breakdown by Category
Other$655,320 (64.1%)
Consulting$219,266 (21.5%)
Travel$97,244 (9.5%)
Research$30,777 (3.0%)
Food & Beverage$19,440 (1.9%)
Education$28.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $655,320 | 127 | 64.1% |
| Consulting Fee | $219,266 | 68 | 21.5% |
| Travel and Lodging | $97,244 | 238 | 9.5% |
| Unspecified | $30,777 | 23 | 3.0% |
| Food and Beverage | $19,440 | 361 | 1.9% |
| Education | $28.26 | 2 | 0.0% |
Payments by Type
General
$991,299
796 transactions
Research
$30,777
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $689,654 | 441 | $0 (2024) |
| Genentech USA, Inc. | $184,555 | 210 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $87,860 | 68 | $0 (2024) |
| Genentech, Inc. | $21,983 | 9 | $0 (2022) |
| Ocular Therapeutix, Inc. | $14,403 | 13 | $0 (2024) |
| Amgen Inc. | $11,774 | 11 | $0 (2024) |
| F. Hoffmann-La Roche AG | $8,048 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,552 | 6 | $0 (2021) |
| Notal Vision, Inc. | $797.50 | 1 | $0 (2023) |
| Allergan, Inc. | $307.14 | 18 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $146,542 | 108 | Regeneron Healthcare Solutions, Inc. ($103,334) |
| 2023 | $115,873 | 76 | Regeneron Healthcare Solutions, Inc. ($90,110) |
| 2022 | $146,789 | 102 | Regeneron Healthcare Solutions, Inc. ($73,200) |
| 2021 | $54,659 | 44 | Regeneron Healthcare Solutions, Inc. ($42,424) |
| 2020 | $86,501 | 59 | Regeneron Healthcare Solutions, Inc. ($65,189) |
| 2019 | $198,714 | 142 | Regeneron Healthcare Solutions, Inc. ($142,029) |
| 2018 | $99,511 | 107 | Regeneron Healthcare Solutions, Inc. ($71,789) |
| 2017 | $173,487 | 181 | Regeneron Healthcare Solutions, Inc. ($101,578) |
All Payment Transactions
819 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/17/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 12/17/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 12/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: EYE CARE | ||||||
| 11/21/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $32.58 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/09/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $123.62 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $552.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/21/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $31.42 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/20/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $113.33 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/19/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $118.28 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $32.54 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $130.35 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,580.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,116.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/24/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $199.46 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $110.98 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: EYE CARE | ||||||
| 09/14/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $220.32 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 09/12/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 09/12/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $323.09 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 09/12/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $64.12 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/10/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY | Regeneron Pharmaceuticals, Inc. | $17,004 | 11 |
| A RANDOMIZED, SINGLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF REPEATED DOSES OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Regeneron Pharmaceuticals, Inc. | $5,037 | 3 |
| PDS PHASE 3 ARCHWAY | F. Hoffmann-La Roche AG | $3,649 | 2 |
| A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy | Regeneron Pharmaceuticals, Inc. | $1,715 | 1 |
| Port Delivery System of Ranibizumab Extension Study | F. Hoffmann-La Roche AG | $1,377 | 1 |
| PRALUENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,266 | 1 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $728.30 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 2,360 | 16,424 | $11.3M | $3.3M |
| 2022 | 8 | 2,057 | 12,919 | $8.3M | $3.1M |
| 2021 | 14 | 2,499 | 15,229 | $9.1M | $3.6M |
| 2020 | 12 | 2,441 | 15,423 | $8.8M | $3.6M |
Total Patients
9,357
Total Services
59,995
Medicare Billing
$13.7M
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 190 | 2,356 | $3.5M | $1.6M | 46.0% |
| J3490 | Unclassified drugs | Office | 2023 | 108 | 230 | $1.7M | $448,759 | 26.9% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 87 | 1,774 | $2.4M | $384,742 | 16.3% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 106 | 1,892 | $949,900 | $348,502 | 36.7% |
| 67028 | Injection of drug into eye | Office | 2023 | 353 | 1,737 | $1.8M | $161,062 | 9.0% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 12 | 4,860 | $508,202 | $134,251 | 26.4% |
| 92134 | Imaging of retina | Office | 2023 | 722 | 2,285 | $171,267 | $63,482 | 37.1% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 17 | 390 | $170,820 | $46,941 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 214 | 230 | $34,270 | $17,669 | 51.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 209 | 309 | $52,530 | $17,600 | 33.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 99 | 99 | $31,360 | $10,038 | 32.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 106 | 107 | $25,680 | $9,933 | 38.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 61 | 61 | $17,543 | $6,886 | 39.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 65 | 65 | $16,770 | $6,505 | 38.8% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 11 | 29 | $3,480 | $1,359 | 39.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 169 | 2,250 | $3.4M | $1.6M | 47.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 168 | 5,622 | $2.8M | $1.2M | 44.5% |
| 67028 | Injection of drug into eye | Office | 2022 | 324 | 1,780 | $1.8M | $162,267 | 8.9% |
| 92134 | Imaging of retina | Office | 2022 | 679 | 2,383 | $178,545 | $64,896 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 266 | 324 | $48,141 | $24,822 | 51.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 229 | 337 | $54,210 | $19,712 | 36.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 148 | 148 | $44,619 | $15,542 | 34.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 74 | 75 | $19,350 | $6,366 | 32.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 222 | 7,425 | $3.7M | $1.9M | 49.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 121 | 1,906 | $2.9M | $1.4M | 49.0% |
About Dr. William Clark, MD
Dr. William Clark, MD is a Ophthalmology healthcare provider based in West Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528057890.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Clark, MD has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $146,542 received in 2024. These payments were reported across 819 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($655,320).
As a Medicare-enrolled provider, Clark has provided services to 9,357 Medicare beneficiaries, totaling 59,995 services with total Medicare billing of $13.7M. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist, Ophthalmology
- Location West Columbia, SC
- Active Since 10/19/2005
- Last Updated 01/23/2025
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1528057890
Products in Payments
- EYLEA (Biological) $380,538
- EYLEA AFLIBERCEPT INJECTION (Biological) $214,353
- EYLEA HD (Biological) $182,430
- Lucentis (Biological) $135,922
- VABYSMO (Drug) $55,236
- Vabysmo (Drug) $16,868
- PAVBLU (Biological) $11,774
- SUSVIMO (Drug) $6,317
- BROLUCIZUMAB (Drug) $1,477
- DEXTENZA (Drug) $903.10
- OZURDEX (Drug) $523.76
- ACTHAR (Biological) $178.01
- Non-Covered Product (Drug) $167.00
- Syfovre (Drug) $148.96
- BEOVU (Drug) $74.65
- Cimerli (Biological) $66.01
- TearLab Osmolarity System (Device) $45.86
- ILUVIEN (Drug) $35.04
- CLARUS (Device) $30.57
- BromSite (bromfenac ophthalmic solution) 0.075% (Drug) $24.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in West Columbia
John Wells, Md, MD
Ophthalmology — Payments: $38,502
Ophthalmology $38,502
Bethany Bray, M.d, M.D
Ophthalmology — Payments: $11,414
Ophthalmology $11,414
Teresa Fowler, Md, MD
Ophthalmology — Payments: $4,971
Ophthalmology $4,971
Dr. John Payne, Md, MD
Ophthalmology — Payments: $1,527
Ophthalmology $1,527
Nitin Nigam, Md, MD
Ophthalmology — Payments: $1,378
Ophthalmology $1,378
David Johnson, Md, MD
Ophthalmology — Payments: $1,034
Ophthalmology $1,034